



Oramed Pharmaceuticals, Inc.
Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem 91390 Israel
Phone: 972-2-566-0001

Issue:
October 22, 2010
All rights reserved!
ceocfointerviews.com

The Most Powerful Name In Corporate News and Information

Oramed Pharmaceuticals, Inc. Has Developed A Technology That Will Allow For The Delivery Of Peptides Intact Orally - Currently In Phase II Clinical Trials

**Healthcare
Pharmaceuticals
(ORMP-OTC: BB)**

**Nadav Kidron, Esq
President, CEO and Director**

BIO:

Nadav has served as President and CEO of Oramed Pharmaceuticals since founding the company in 2006. An entrepreneur whose career has included managerial roles in a variety of companies and organizations. Nadav is an Advisory Board Member for The Trendlines Group, a group that invests in and develops innovation-based businesses. Nadav holds a Bachelor of Law Degree and a Masters in Business Administration from Bar Ilan University. He is member of the Israeli Bar Association.

Company Profile:

Oramed Pharmaceuticals (OTC: ORMP.OB) is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

**Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com**

CEOCFO: Mr. Kidron, what was your vision when you founded Oramed Pharmaceuticals?

Mr. Kidron: The vision for Oramed Pharmaceuticals when it was founded was to take the technology that enables us to convert drugs and vaccines that currently can only be given via injection, and to give them orally. In addition, we wanted to take our flagship product, which is oral insulin and to bring it into the market so tens of millions of patients out there can enjoy healthier and better lives because of this technology.

CEOCFO: What is the primary reason it hasn't been done so far, and what is it that Oramed knows or has that will allow you to do this?

Mr. Kidron: The problem is that it is considered to be impossible to deliver drugs that are made out of peptides orally because of two obstacles; one is the degradation of the protein as it goes through the body and the second one is the issue of the size of the proteins, which can make it harder for drugs to be delivered to the right area of the body. What Oramed has done after many years, almost thirty years of work and trial and error, is that we have developed a technology that overcomes the two obstacles of degradation and size and has enabled the delivery of the peptides intact being administered orally.

CEOCFO: Where are you in the process today?

Mr. Kidron: Our flagship product oral Insulin has already been administered over 1,500 doses, 15,000 capsules in humans, and we are about to start Phase II trial under FDA and our plan is to service in the 1st Quarter of 2011.

CEOCFO: Are you doing this on your own, are you partnering?

Mr. Kidron: So far we are doing it on our own. Our game plan is to partner later down the line, I assume near the beginning or toward the end of Phase II, will be the appropriate time to partner.

CEOCFO: Are there any side-effects or potential problems or has it been smooth sailing so far?

Mr. Kidron: So far the safety has been a smooth sail. I would like to emphasize that all the materials we use are safe materials, so that is why we are not as worried for safety issues. Also we do not develop a new drug, what we do is develop delivery technology, so we are using the same insulin that has been used since 1943. However, we have just found another way to deliver it, so that is why we do not foresee a reason for safety issues.

CEOCFO: Diabetes is a common disease; what is the competitive landscape in development of new methods of delivery?

Mr. Kidron: There are a few companies that work on alternative routes of delivery of insulin such as inhaling, insulin patch, and oral insulin. We think the oral insulin is different in essence only from the patient compliance point of view. Also it is a logical that its benefits lead us to believe that oral insulin should be looked at differently than the alternative routes of deliver.

CEOCFO: Insulin having been around for a long time, is it that people are aware of it and therefore are not concerned about the long term effect?

Mr. Kidron: Yes, and that is because everybody knows what insulin does.

CEOCFO: You have some other things you are working on as well, will you tell us about those?

Mr. Kidron: Our second product in the pipeline is a drug called GEO21 Analog, which is a great drug that reduces the glucose level in diabetics and with the commercial version that is available today people feel nauseous when they take the injection. We have been working on an oral version and the oral version so far, and we only studied clinical trials, we had no side-effects of people feeling nauseous after taking it. The idea is to accelerate that development as well, so diabetics will be able to take GEO21 Analog orally and enjoy only the easier route of delivery, meaning taking it orally versus taking it through injection. In addition, they will enjoy the benefits of saving the side-effects that come along with other methods of administration.

CEOCFO: What is the financial picture for Oramed today?

Mr. Kidron: Oramed is a publicly traded company on the OTC. I can tell you that we run it on a very low budget. Right now, we have sufficient funds to continue with the GEO21 Analog Phase II, to file the IND for the FDA. Prior to studying the actual FDA trial, we will need to raise additional funds to support the FDA trials.

CEOCFO: Will you tell us about your agreement with Sanofi-Aventis?

Mr. Kidron: Sanofi-Aventis is one of the top insulin sites in the world, and they

look for potential consumers over the next few years. We have to make sure that not only do we have a technology that works, but that at the end of the day the patients out there and the end user will be able to get what he needs. So in order to insure that, we wanted to make sure that we could partner with the right organization that has the ability to produce their insulin in those amounts, because it is going to be big, big, big amounts. Therefore, after a few months

The vision for Oramed Pharmaceuticals when it was founded was to take the technology that enables us to convert drugs and vaccines that currently can only be given via injection, and to give them orally. In addition, we wanted to take our flagship product, which is oral insulin and to bring it into the market so tens of millions of patients out there can enjoy healthier and better lives because of this technology.

- Nadav Kidron, Esq

back and forth in negotiations, we agreed to use them as a supplier, and they agreed to use us as their client and we are looking forward for a long and fruitful relationship with a very serious company that they are.

CEOCFO: Why does Oramed stand out to potential investors?

Mr. Kidron: Oramed has a product that has a very clear upside which is huge. What makes Oramed unique is that if you look at the people that associated themselves with Oramed, you see the top peo-

ple in the industry; these are some of the key opinion leaders that are involved in the company. Think that it is not a new drug, but a delivery system that works and you see the potential of the product. Then there is a tremendous potential there for investors to realize the value of their investments, hopefully within a shorter time than a longer time.

CEOCFO: What might people misunderstand about Oramed and about what you are doing that they really should understand?

Mr. Kidron: There is one point that we always have a hard time conveying it to people; when we speak about oral use, we assume everybody thinks about oral versus injection. However, when we talk about oral insulin we talk about an oral prior to injection, which means most of the time today they start with oral drugs, and even then, they

move to the injection. When we introduce oral insulin, we want to introduce an earlier treatment that will avoid or prolong the time that the patients will need to use the injection by giving them insulin as an earlier treatment. By doing, so we talk about oral insulin not only as a patients compliance benefit, but rather as a new paradigm to treat diabetics in a better way in many ways.

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

**Oramed Pharmaceuticals, Inc.
Hi-Tech Park 2/5 Givat Ram
PO Box 39098
Jerusalem 91390 Israel
Phone: 972-2-566-0001**